Jenburkt Pharmaceuticals
- Market cap
- ₹ 376 Cr.
- P/E
- 10.8x
- P/B
- 1.95x
- 52-week range
- 845 – 1,073.9
- ROE
- 20%
- ROCE
- 27%
- Dividend yield
- 2.4%
- Debt / equity
- 0.01
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Jenburkt Pharmaceuticals Limited is an India-based company that is engaged in the business of manufacturing, producing, developing and marketing a range of branded pharmaceuticals and healthcare products. The Company offers pharmaceutical products for various therapeutic areas, including analgesic and antipyretics, anthelmintics, anti-arthritics, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer products, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. The Company's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets, Topcal-M Tablets, Powergesic, ZIX P Tablet, and others. The Company's manufacturing plant is in Sihor, Gujarat.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Jenburkt Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)10.8 against a typical 34.3: cheaper than most peers (1st = cheapest).24th of 220
- Sales growth−0.1% against a typical +15.6% from a year earlier.148th of 197
- Profit growth−24.4% against a typical +18.9% from a year earlier.118th of 160
- Size₹ 375.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).105th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 38 | 36 | 39 | 33 | 41 | 37 | 41 | 36 | 46 | 43 | 45 | 36 |
| Expenses | 29 | 28 | 29 | 23 | 30 | 28 | 30 | 27 | 32 | 36 | 30 | 29 |
| Operating Profit | 9 | 7 | 10 | 9 | 11 | 9 | 11 | 9 | 13 | 7 | 14 | 6 |
| OPM % | 23.8% | 20.2% | 25.4% | 28.5% | 27.7% | 23.9% | 26.5% | 25.2% | 28.8% | 17.3% | 31.9% | 17% |
| Other Income | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 10 | 8 | 10 | 10 | 13 | 10 | 12 | 10 | 14 | 8 | 14 | 7 |
| Tax % | 23.3% | 31.1% | 23.9% | 26.3% | 23.3% | 31.7% | 27.9% | 23.5% | 29.1% | 28.6% | 20.9% | 13% |
| Net Profit | 7 | 5 | 8 | 7 | 10 | 7 | 9 | 8 | 10 | 6 | 11 | 6 |
| EPS in Rs | 16.59 | 12.24 | 17.86 | 16.81 | 21.75 | 14.75 | 19.35 | 17.65 | 23.02 | 13.44 | 24.58 | 13.35 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 6%
- 5 Years
- 9%
- 3 Years
- 7%
- TTM
- 9%
- 10 Years
- 13%
- 5 Years
- 18%
- 3 Years
- 15%
- TTM
- 10%
- 10 Years
- 11%
- 5 Years
- 16%
- 3 Years
- 14%
- TTM
- —
- 10 Years
- 21%
- 5 Years
- 20%
- 3 Years
- 20%
- TTM
- —
P/E and EPS over time
Daily price to earnings ratio.
Peers
Listed companies in the same business.
| Jenburkt Pharmaceuticals | ₹ 876.05 | ₹ 376 Cr. | 10.8x | 2x | 20% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 39.5x | 5.7x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 78.8x | 12.3x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 74.5x | 19.7x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28.7x | 3.5x | — | 11.9% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.8x | 4.2x | 19.7% | 18.5% |
Management
- Ashish Uttam Bhuta
- Chairman, Managing Director
- Dilip H. Bhuta
- Whole Time Director, Chief Financial Officer
- Ashish R. Shah
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.